Please login to the form below
Spark Therapeutics
This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
CHMP backs Spark’s Luxturna, but rejects Sarepta again
CHMP backs Spark’ s Luxturna, but rejects Sarepta again. Contrasting fortunes for rare disease treatments. ... Spark Therapeutics looks set for approval of its eye disorder gene therapy Luxturna on both sides of the Atlantic after getting a green light
-
Spark sputters on haemophilia A gene therapy safety scare
Spark sputters on haemophilia A gene therapy safety scare. Investors compare data unfavourably with BioMarin rival. ... Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its
-
Bluebird’s first gene therapy gets European fast track
recommendation, while Spark Therapeutics’gene therapy Luxturna looks set to gain CHMP recommendation by the end of 2018.
-
Pfizer enters late-stage haemophilia B gene therapy trial
Pfizer’s phase III programme will test the Spark Therapeutics-developed compound after it gathers safety and efficacy data of current factor IX prophylaxis replacement therapy as a lead-in study. ... We look forward to the opportunity to continue the
-
Axovant licenses another gene therapy as new strategy beds in
developed by Oxford BioMedica – and after Axovant hired former Spark Therapeutics ’exec Fraser Wright to bolt on expertise in the gene therapy sector.
More from news
Approximately 9 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’drugs and, in
-
Health on instalment
For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.
-
The rise of real-world evidence
Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.
-
Deal Watch December 2016
and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Industry appointments
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’experience and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
-
Medical/ Scientific Director
-
Salary TBC
-
Senior Medical Writer
-
Competitive Salary
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Associate Medical Director
-
Highly Competitive
-
Associate Director
-
£75, 000-90, 000
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
Subscribe to our email news alerts
- Worldwide Clear Aligner Market to grow at a CAGR of 16.15% By 2023
- Worldwide Prenatal and New-born Genetic Testing Market Set to Register 11.9% CAGR During 2018-2024
- Medical Biomimetics Market soaring at 5.5% CAGR to Hit USD 34.4 Billion By 2024
- Medical Marijuana Market to Soar at 36% CAGR to 2024
- Worldwide Medical Ultrasound Imaging Equipment Market to Witness Robust Expansion Throughout the Forecast Period 2018 – 2023
- Worldwide Home Infusion Therapy Market Soaring at 9% CAGR to Hit USD 28 Billion by 2024
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
